Medicines Co buys antibiotic-maker Rempex
Dec 4 (Reuters) - Medicines Co on Wednesday said it acquired privately held Rempex Pharmaceuticals Inc, which develops medicines against drug-resistant bacteria, for $140 million and potential future milestone payments of up to $334 million.
Medicines Company said it acquires several anti-infective drugs as part of the deal, including a promising experimental medicine called Carbavance that has completed early-stage trials.
The company said it will continue to develop other experimental drugs from Rempex that also treat gram-negative bacteria in hospital settings.
- Missing jet may have strayed toward Andaman Sea: Malaysian air force |
- NYC buildings explosion kills two, more missing
- EU moves towards travel bans, asset freezes for Russians |
- Malaysia military source says missing jet veered to west |
- Exclusive: EU approves framework for asset freezes, travel bans on Russia